title: Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma.
abstract: The malignancy of alveolar rhabdomyosarcoma (ARMS) has been linked to expression of the PAX3-FKHR chimeric gene. To understand the effect of this gene, we used RNAi to knock down its expression (without affecting the expressions of either PAX3 or FKHR) in human ARMS cell lines. Down-regulating PAX3-FKHR caused (a) tumor cells to accumulate in the G1 phase, inhibiting the rate of cellular proliferation, (b) a reduction in the levels of the MET, reducing cell motility stimulated by HGF, and (c) induction of the myogenic differentiation gene, myogenin, and muscle differentiation (morphologic change and the expression of muscle specific proteins, desmin, and myosin heavy chain). These results suggest that PAX3-FKHR in ARMS cells promotes malignant phenotypes such as proliferation, motility, and to suppress differentiation.
authors.affiliation: Department of Pediatrics, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramchi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
authors.forename: Ken
authors.initials: K
authors.lastname: Kikuchi
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Tsuchiya
authors.forename: Osamu
authors.initials: O
authors.lastname: Otabe
authors.forename: Takahiro
authors.initials: T
authors.lastname: Gotoh
authors.forename: Shinichi
authors.initials: S
authors.lastname: Tamura
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Katsumi
authors.forename: Shigeki
authors.initials: S
authors.lastname: Yagyu
authors.forename: Satoko
authors.initials: S
authors.lastname: Tsubai-Shimizu
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Miyachi
authors.forename: Tomoko
authors.initials: T
authors.lastname: Iehara
authors.forename: Hajime
authors.initials: H
authors.lastname: Hosoi
mesh_terms: D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D006801:Humans; D024510:Muscle Development / Q000187:drug effects / Q000235:genetics; D019042:Muscle Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D015514:Oncogene Proteins, Fusion / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D010641:Phenotype; D034741:RNA, Small Interfering / Q000494:pharmacology; D018232:Rhabdomyosarcoma, Alveolar / Q000235:genetics / Q000378:metabolism / Q000473:pathology*
chemical_list: D015514:Oncogene Proteins, Fusion; C523321:PAX3-FKHR fusion protein, human; D034741:RNA, Small Interfering